TrialThe oncologist2022

Phase II Clinical and Translational Study of Everolimus ± Paclitaxel as First-Line Therapy in Cisplatin-Ineligible Advanced Urothelial Carcinoma.

Tomi Jun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.